Interestingly, the results of antibody blockade assays in the combination treatment group were different, where blocking either CD8+ T or CD4+ T cells resulted in the partial inhibition of tumor growth, indicating the CD8+ and CD4+ subsets each played important roles in anti-tumor effects. The gene discussed is CD8A; the disease is neoplasm.